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Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as
well as associated comorbid conditions including obsessive-compulsive disorder (OCD),
attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present
in a substantial number of patients. Although randomized controlled trials including a
large number of patients are still missing, aripiprazole is currently considered as a first
choice drug for the treatment of tics. The aim of this study was to further investigate
efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically,
we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory
urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that
influence a patient’s decision in electing for-or against- pharmacological treatment. In this
prospective uncontrolled open-label study, we included 44 patients and used a number
of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during
treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing
treatment for their tics with aripiprazole and completed follow-up assessments after 4–6
weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics,
but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend
toward improvement of other comorbidities including depression, anxiety, and ADHD;
(3) neither severity of tics, nor PU or QoL influenced patients’ decisions for or against
treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide
in favor of, while patients with comorbid ADHD tended to decide against tic treatment;
(4) most frequently reported adverse effects were sleeping problems; (5) patients’ QoL
was mostly impaired by comorbid depression. Our results suggest that aripiprazole
may improve associated comorbid conditions in addition to tics in patients with GTS.
It can be hypothesized that these beneficial effects are related to aripiprazole’s adaptive
pharmacological profile, which exhibits an influence on the dopaminergic as well as a
number of other neurotransmitter systems. For the first time, our data provide evidence
that patients’ decision making process for or against medical treatment is influenced by
other factors than tic severity and QoL.
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INTRODUCTION
Gilles de la Tourette Syndrome (GTS) is a chronic
neuropsychiatric disorder with childhood onset. GTS is
characterized by multiple motor and one or more vocal tics
(American Psychiatric Association, 2013). Tics are defined as
rapid, non-rhythmic, involuntary movements or vocalizations
that are misplaced in context and time (Jankovic, 1997). The
majority of adult patients is able to suppress their tics voluntarily
(Müller-Vahl et al., 2014) and most adults report premonitory
urge (PU) sensations prior to their tics (Leckman et al., 1993).
Contrary to the general belief and patients’ reports, recent studies
have been suggested that there is no direct relation between tic
severity, PU, and tic suppression (Ganos et al., 2012; Müller-Vahl
et al., 2014).
Today, it is well-known that 80–90% of patients with
GTS in addition suffer from comorbid disorders such as
obsessive-compulsive disorder (OCD), depression, anxiety, and
attention deficit/hyperactivity disorder (ADHD) (Freeman et al.,
2000; Leckman, 2002). At such, there is an ongoing debate
concerning the number of valid sub-classifications within the
GTS spectrum. For example, Robertson (2000) suggested the
following classification: pure GTS (tics only), full-blown GTS
(plus complex tics), and GTS plus (including comorbidities).
More recent work has provided strong evidence that comorbid
OCD, anxiety, and depression belong to the GTS spectrum,
while comorbid ADHD should be classified as a separate
problem (Lebowitz et al., 2012; Hirschtritt et al., 2015; Trillini
and Müller-Vahl, 2015a). In adult patients with GTS, it has
been demonstrated that health-related quality of life (QoL) is
remarkably influenced by psychiatric comorbidities, in particular
depression and OCD (Müller-Vahl et al., 2010; Jalenques et al.,
2012).
Although varied therapeutic strategies currently being
used to treat patients with GTS (e.g., behavioral therapy,
pharmacotherapy, and deep brain stimulation), no currently
available intervention has been shown to be able to effectively
target the multiple symptoms associated with GTS. With respect
to pharmacological treatment, current recommendations are
based on a small number of controlled or uncontrolled studies,
as large scale and longitudinal randomized controlled trials
(RCTs) including a larger number of patients over a longer
period of time have not been undertaken to date (Roessner
et al., 2011; Weisman et al., 2014). Nevertheless, there is general
agreement that substances that affect the dopaminergic system
(antipsychotics) are most effective in the treatment of tics
(Singer, 2010).
Since the discovery of its tic suppressive effects in the 1970s,
haloperidol still stands as the sole formally approved medication
for the treatment of GTS in most European countries. However,
many clinicians no longer recommend it as haloperidol exhibits
a significant adverse effect (AE) profile (Shapiro et al., 1973).
Although not licensed, other (second generation)
antipsychotics such as risperidone, sulpiride, tiapride, and
in particular aripiprazole are the most common medications
used today for the treatment of tics, mainly as a result of their
more favorable side effect profile. Within this class of drugs,
aripiprazole has become the preferred antipsychotic in many
centers for treating tics (Roessner et al., 2011; Hartmann and
Worbe, 2013), since it is suggested that it causes less side effects
(Wenzel et al., 2012) and is also effective in severely affected
and otherwise treatment-refractory patients (Roessner et al.,
2011).
Since 2004, various reports exploring the efficacy and safety of
aripiprazole in the treatment of tics in GTS have been published.
These include 28 case reports (Hounie et al., 2004; Dehning
et al., 2005; Kastrup et al., 2005; Murphy et al., 2005, 2009;
Padala et al., 2005; Bubl et al., 2006; Constant et al., 2006;
Davies et al., 2006; Duane, 2006; Fountoulakis et al., 2006; Yoo
et al., 2006, 2007; Ben Djebara et al., 2008; Budman et al.,
2008; Findling et al., 2008; Seo et al., 2008; Winter et al., 2008;
Ikenouchi-Sugita et al., 2009; Kawohl et al., 2009; Lai, 2009;
Lyon et al., 2009; Cui et al., 2010; Frölich et al., 2010; Masi
et al., 2012; Wenzel et al., 2012; Diomšina et al., 2015; Mazlum
et al., 2015), 3 controlled trials (Gulisano et al., 2011; Yoo et al.,
2013; Ghanizadeh and Haghighi, 2014), and 1 systematic review
(Ghanizadeh, 2012). However, less than 40% of these reports have
investigated the effects of aripiprazole on adult populations. In
the two largest children only studies, aripiprazole was found to be
superior to placebo (Yoo et al., 2013) and comparably effective as
risperidone (Ghanizadeh and Haghighi, 2014) with respect to the
improvement of tics and QoL. In general, aripiprazole was well
tolerated. The most frequently reported AEs were drowsiness,
increased appetite and weight gain. Based on these preliminary
data, Ghanizadeh (2012) concluded in his systematic review that
aripiprazole is effective in the treatment of tics in both adults
and children with GTS with an adverse effect profile that seems
to be safer than in other antipsychotic drugs. To the best of
our knowledge, so far, no data are available on the effect of
aripiprazole on PU.
Interestingly, in most of these studies effects of aripiprazole
on tics have been investigated, but not on psychiatric
comorbidities. Since aripiprazole influences the dopaminergic,
and other neurotransmitter systems including the serotonergic,
GABAergic, and glutamatergic systems (De Bartolomeis et al.,
2015), it can be speculated that in addition to tics, it ameliorates
comorbid symptoms including OCD, ADHD, depression, rage
attacks, and anxiety. As a result in this work, we aimed at
investigating the efficacy and safety of aripiprazole in a relatively
large sample of unmedicated adult patients with GTS, specifically
focusing on its effects on tics, QoL, PU, and psychiatric
comorbidities (OCD, ADHD, depression, and anxiety). Since no
other psychotropic drugs were allowed, influences from other
drugs or interactions with other substances could be excluded.
Our study design additionally allowed us to investigate difference
in clinical features between patients who elected for (and against)
treatment with aripiprazole.
We hypothesized that (1) aripiprazole improves both tics and
behavioral problems in unmedicated adult patients with GTS and
that (2) tic severity and QoL have the strongest influence on
patients’ decision for treatment with aripiprazole.
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METHODS
This study has been performed as part of the EU-funded
Marie Curie Initial Training Network (ITN) TS-EUROTRAIN
(FP7-PEOPLE-2012-ITN, Grant Agr.No.316978). Patients were
investigated at baseline and following treatment with aripiprazole
using a variety of clinical tools. We decided to use both self-
and expert ratings in order to obtain higher validity. Self-
ratings solely based on patient’s judgment. Expert-ratings were
performed by a team of 2 psychologists and 1 physician either at
the HannoverMedical School (MHH) or the Institute for Human
Cognitive and Brain Sciences at the Max-Planck-Institute in
Leipzig. In most cases, the respective patient was assessed at
baseline and follow-up by the same rater. In addition, in all
patients Magnetic Resonance Imaging (MRI) was performed (at
the Institute for HumanCognitive and Brain Sciences at theMax-
Planck-Institute, Leipzig) both at baseline and after treatment
with aripiprazole. Neuroimaging results of this study will be
published elsewhere.
Subjects
In this study, 44 patients with GTS according to DSM-5 were
included. Patients using any psychoactive substances underwent
a 4-week washout period before participation. Exclusion criteria
were age <18 and >65 years, inability to lie still in the MRI,
MRI contraindications, pregnancy, and breast-feeding. Patients
were recruited from the Clinic of Psychiatry, Socialpsychiatry
and Psychotherapy at the MHH and via newsletters, internet
and the German Tourette advocacy groups between May 2014
and October 2015. Ethics approval was granted by the ethics
committees both at the MHH and the University of Leipzig.
All participants gave written informed consent before entering
the study. Patients received a monetary compensation for study
participation.
Design
After baseline investigations, to all patients aripiprazole was
offered for treatment of tics. Aripiprazole was gradually up-
titrated every 3 days starting with 2.5mg/day up to a maximum
dose of 30mg/day. Dosage was increased individually until
the patient reached his/her individually tolerated maximum
dose or best tic improvement defined on the basis of patient’s
judgment and investigator’s assessments. Thus, no target dose
was predefined and the final dose could range from 2.5 to
30mg/day. Aripiprazole was administered once daily in the
morning or in case of significant sedation, alternatively in the
evening. In those patients, who decided for treatment with
aripiprazole, investigations were performed again after 4–6 weeks
treatment with aripiprazole. After study completion, patients
could decide either to continue or to discontinue treatment.
Clinical Assessments
All patients underwent a neuropsychiatric interview and
a comprehensive clinical assessment battery including
measurements of tics, PU, QoL, and psychiatric comorbidities
(OCD, ADHD, depression, anxiety, and autism).
Assessments for Tics
(1) Yale Global Tic Severity Scale (YGTSS) (Leckman et al.,
1989): The YGTSS is a scale for the assessment of number,
frequency, intensity, complexity, and interference of motor
and vocal tics, and for the estimation of the global
impairment; “total tic score” (TTS) (range, 0–50), divided in
“motor tic score” (MT) (range, 0–25) and “vocal tic score”
(VT) (range, 0–25), “overall impairment score” (range, 0–
50), and “global score” (GS) (range, 0–100).
(2) Modified Rush Video-Based Tic Scale (MRVS) (Goetz et al.,
1999): The 10-min film protocol includes full frontal body
(far) and head/shoulders only (near) views with and without
an examiner in the room lasting 2.5min each. For tic rating,
only two (far and near body views) 1-min recordings with no
examiner present were scored rating 5 domains: number of
body areas involved (range, 0–4), motor tic frequency (range,
0–4), vocal tic frequency (range, 0–4), motor tic severity
(range, 0–4), vocal tic severity (range, 0–4) resulting in the
total score (range, 0–20).
Assessment for PU
Premonitory Urge for Tics Scale (PUTS) (Woods et al., 2005):
The PUTS is a self-rating for PU (range 0–36); the higher the sum,
the higher the PU.
Assessments for Health-Related QoL
The Gilles de la Tourette Syndrome Quality of Life Scale (GTS-
QoL) and satisfaction-with-life visual analog scale (GTS-QoL-
VAS) (Cavanna et al., 2008) were used to assess health-related
QoL (range, 0–100, each): the higher the GTS-QoL score, the
lower the patients’ QoL; the higher the GTS-QoL-VAS, the higher
the satisfaction-with-life.
Assessments for Psychiatric Symptoms
(1) M.I.N.I. International Neuropsychiatric Interview 5.0
(Sheehan et al., 2006): TheM.I.N.I. is an abbreviated version
of the Structured Clinical Interview for DSM-IV (SCID)
(Wittchen et al., 1997) based on ICD-10 classifications
of mental and behavioral disorders. It is divided into 16
modules, each corresponding to a diagnostic category.
At the end of each module, diagnostic box(es) allow the
interviewer to specify whether diagnostic criteria for the
respective clinically relevant disease are met (Goodman
et al., 1989).
(2) Montgomery Asberg Depression Scale (MADRS)
(Montgomery and Asberg, 1979): MADRS is an examiner
rating for the diagnosis and severity of depression (range,
0–60), 0–6 = normal/symptoms absent, 7–19 = mild
depression, 20–34 = moderate depression, ≥35 = severe
depression.
(3) Beck Depression Inventory II (BDI-II) (Beck et al., 1996;
Hautzinger et al., 2006): BDI-II is a self-report scale
for depression (range, 0–63); 0–12 = no depressive
symptoms, 13–19 = mild, 20–28 = medium, and ≥29 =
severe depressive symptoms. Cut-off for clinically relevant
depressive symptoms is ≥18.
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(4) Beck Anxiety Inventory (BAI) (Beck et al., 1988; Margraf
and Ehlers, 2007): This self-rating was used to measure
anxiety symptoms (range, 0–63), 0–7 = minimum level
anxiety, 8–15 = mild, 16–25 = medium, and ≥26 =
serious level anxiety. Cut-off for clinically relevant anxiety
symptoms is ≥26.
(5) Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
(Goodman et al., 1989): The Y-BOCS was used to assess
obsessive-compulsive symptoms, obsessions (range, 0–24),
cut-off for clinical relevant obsessions ≥10, compulsions
(range, 0–24), cut-off for clinical relevant compulsions
≥10, for both (range, 0–48), cut-off ≥16.
(6) Obsessive-Compulsive Inventory Revised (OCI-R) (Foa
et al., 2009): in addition, we used the OCI-R for the
measurement of OCD and obsessive-compulsive behavior
(OCB). It is a self-rating-scale including a five-point Likert-
type scale from 0 (“not at all”) to 4 (“extremely”). The
scale consists of 6 three-item subscales (range, 0–12 each):
washing (cut-off= 3), checking (cut-off= 5), ordering (cut-
off= 7), obsessing (cut off= 5), hoarding (cut-off= 5) and
mental neutralization (cut-off= 3).
(7) DSM-IV symptom list for ADHD (Rösler et al., 2004):
this retrospective questionnaire (range, 0–18) includes
2 domains; attention deficit disorder (cut-off ≥6) and
hyperactivity disorder (cut-off ≥6).
(8) Wender Utah Rating Scale (WURS-k) (Ward et al., 1993;
Retz-Junginger et al., 2003): The WURS-k was used as
a retrospective self-rating (range, 0–100), cut-off ≥30
suggests the diagnosis of ADHD.
(9) Conners Adult ADHDRating Scale (CAARS) (Christiansen
et al., 2011): The CAARS was used to measure current
symptoms (range, 0–198). Raw scores have to be
converted into T-scores (cut-off ≥65) for each category:
inattention/memory problems, hyperactivity/restlessness,
impulsivity/emotional lability, problems with self-concept,
DSM-IV inattentive symptoms, DSM-IV hyperactive-
impulsive symptoms, DSM-IV ADHD symptoms total, and
ADHD index.
(10) Autism-Spectrum-Quotient (AQ) (Baron-Cohen et al.,
2001): The AQ was used to measure autistic traits (range,
0–50), cut-off ≥32. The AQ cannot be used to make the
diagnosis of an autism spectrum disorder.
Diagnoses of Comorbidities
In order to (1) achieve a reliable diagnosis of psychiatric
comorbidities, (2) reduce the rate of type-I and type-II errors,
and (3) avoid a bias due to erroneous self-perception, we utilized
a number of assessment tools, including both self-rating and
expert-rating scales, to diagnose each condition. Accordingly, the
particular diagnoses were made as follows:
Diagnosis of depression: For the diagnosis of depression,
results of both M.I.N.I., MADRS, and BDI-II were taken into
account as suggested earlier (Uher et al., 2008; Van Noorden
et al., 2012; Van der Lem et al., 2015). Patients were diagnosed
as depressive if they fulfilled (1) the M.I.N.I. category “major
depressive episode current” and reach a BDI-II score≥18 and/or
a MADRS score≥7 or (2) reached both a BDI-II score≥18 and a
MADRS score ≥7.
Diagnosis of anxiety disorder: For the diagnosis of anxiety
disorder, results of both M.I.N.I. and BAI were taken into
consideration (Phan et al., 2016). Anxiety disorder was diagnosed
if the patients (1) fulfilled the category “panic disorder
current,” “agoraphobia current,” “social phobia current,” and/or
“generalized anxiety disorder current (GAD)” according to
M.I.N.I. and reach a BAI score ≥8 or (2) reached a BAI score
≥26.
Diagnosis of OCD: 3 different rating scales were used to assess
OCD in which the patient had to fulfill the M.I.N.I. category
“OCD current” and the respective cut-off values of the Y-BOCS
and/or the OCI-R (in at least one subscale).
Diagnosis of ADHD: As suggested elsewhere, the diagnosis
of current ADHD was made based on results obtained from
DSM-IV symptom list, WURS-k, and CAARS (Taylor et al., 2011;
Smyth and Meier, 2016). Patients were diagnosed with ADHD
if they satisfied respective cut-off values of WURS-k or DSM-IV
symptom list and of ≥4/8 CAARS categories.
GTS Subgroup Classification and Comorbidity Score
Depending on the presence of comorbid diagnoses as defined
above, the following subgroup classifications were used for
further analysis: “GTS only” (without comorbid OCD, ADHD,
depression, and anxiety disorder) and “GTS plus” (with ≥1
of above mentioned comorbidities). In addition, we defined
the following sub-classifications depending on the kind of
the psychiatric comorbidities: (1) “GTS+OCD” (excluding
ADHD, but possibly other comorbidities), (2) “GTS+ADHD”
(excluding OCD, but possibly other comorbidities), and (3)
“GTS+OCD+ADHD” (and possibly other comorbidities).
Patients not belonging to one of these subgroups were classified
as “others.” Furthermore, a comorbidity score representing the
individual’s number of comorbid disorders (including OCD,
ADHD, depression, and anxiety as defined above, range, 0–4)
was calculated as suggested earlier (Freeman et al., 2000).
Serum Levels of Aripiprazole
In order to investigate patient adherence, to quantify aripiprazole
serum concentration and to correlate serum levels of aripiprazole
with oral dosages of aripiprazole, we took 10ml of blood for
analysis of drug serum concentrations at follow-up.
Statistical Analyses
Statistical analysis was performed in the Statistical Package for
Social Sciences (SPSS, Version 20.0 for Windows). Descriptive
statistics (means, standard deviation, frequencies) were
computed for all baseline characteristics. Associations between
clinical assessments at baseline and follow up were examined
via the Spearman rank correlation coefficient. In particular,
correlates of PU, GTS-QoL, and GTS-QoL-VAS were computed.
All statistical tests were two-sided and the alpha value was set at
0.05. No adjustment for multiple comparison (e.g., Bonferroni)
was performed due to the exploratory nature of the analysis.
Treatment effects in terms of pre/post-comparison of symptom
severity of tics and comorbidities were carried out using the
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Wilcoxon-Mann-Whitney-Test for paired samples. The baseline
characteristics of patients electing for- and against-treatment
with aripiprazole were compared using the Wilcoxon-Mann-
Whitney-Test for unpaired samples. Aripiprazole serum levels




A total of 44 patients were included in the study [mean age= 39.4
(±12.2 (SD)] years, range, 18–58 years, female = 9, male = 35).
Mean tic severity was 22.2 [(±8.5), range, 3–39] according to
YGTSS-TTS and 9.6 [(±5.0), range, 0–18] according to MRVS.
The sample exhibited a mean comorbidity score of 1.36 (range,
0–4) with a total of 9, 5, and 4 patients exhibiting 2, 3, and 4
comorbid conditions respectively. The diagnosis for comorbid
OCD was made in 15 patients, for ADHD in 16, for depression
in 14, and for anxiety in 15 patients. The subgroups of GTS
depending on psychiatric comorbidities at baseline are shown
in Table 1. Detailed clinical characteristics of the sample are
presented in Table 2.
Table 3 displays baseline correlates of PUTS, GTS-QoL, and
GTS-QoL-VAS. PU (according to PUTS) did not correlate with
tic severity [YGTSS-TTS (r = 0.281) and MRVS (r = 0.042)], but
with Y-BOCS (r = 0.340), DSM-IV attention (r = 0.313), and
CAARS ADHD total (r = 0.411).
QoL (as assessed by GTS-QoL) correlated with a number
of baseline characteristics significantly. We found the strongest
correlations with assessments for depression [BDI-II (r = 0.776)
and MADRS (r = 0.790)], followed by those for anxiety
[BAI (r = 0.672)], ADHD [CAARS ADHD total (r = 0.583),
WURS-k (r = 0.421), DSM-IV attention (r = 0.360)], and OCD
[OCI-R (r = 0.571)]. Tic severity had only medium strength
correlation [YGTSS-TTS (r = 0.461)]. Satisfaction-with-life
TABLE 1 | Subgroups of GTS depending on psychiatric comorbidities.
GTS Subgroups Baseline Follow-up
Overall Patients not Patients
treated with treated with
aripiprazole aripiprazole
N = 44 N = 26 N = 18 N = 18
GTS only 15 9 6 8
GTS+comorbidities 29 17 12 10
GTS+OCD 8 2 6 2
GTS+ADHD 8 8 1 1
GTS+OCD+ADHD 7 4 3 2
Others 6 3 2 5
GTS, Gilles de la Tourette Syndrome; OCD, Obsessive-Compulsive Disorder; ADHD,
Attention-Deficit/Hyperactivity Disorder; N, Number of cases; Others, Patients with
comorbidities who does not fulfill criteria for one of the defined subgroups (comorbidities
that fell into this category were depression N = 6, anxiety N = 6, depression+anxiety
N= 4). Comorbidities include OCD, ADHD, depression, and anxiety (diagnoses as defined
above).
(according to GTS-QoL-VAS) correlated with several baseline
characteristics significantly: assessments for depression [BDI-II
(r = −0.680) and MADRS (r = −0.731)], followed by those
for anxiety [BAI (r =−0.577)] and OCD [Y-BOCS (r = −0.322)
and OCI-R (r = −0.509)]. While YGTSS-TTS (r = −0.379) and
MRVS (r = −0.330) had only weak correlations with GTS-QoL-
VAS, YGTSS-GS correlated strongly with it (r = −0.609). There
were no significant correlations with ADHDmeasures.
Autistic traits demonstrated no significant correlations with
any of the above mentioned variables. Differences between males
and females were not detected in any of the tests.
Treatment Effects of Aripiprazole
18 of 44 patients elected for commencing treatment of their
tics with aripiprazole. At follow-up, mean dosage of aripiprazole
was 12.2mg (median = 10mg, range, 2.5–30mg). All patients
reported that they had reached their individual target dosage at
the follow-up visit.
Tics and PU
Treatment with aripiprazole resulted in a significant tic reduction
according to YGTSS (YGTSS-TTS: difference: −3.5, p = 0.027,
YGTSS-MT: difference: −1.9, p = 0.037, YGTSS-VT: difference:
−1.6, p = 0.045, YGTSS-GS: difference: −15.0, p = 0.002) and
MRVS (difference:−2.4, p= 0.022) (see Table 2).
In contrast, aripiprazole did not result in a significant
improvement of PU as assessed by PUTS (p = 0.917).
Comparable to results at baseline, we observed no correlations
between PU (according to PUTS) and tic severity (according
to YGTSS and MRVS) for on-treatment patients. In contrast
to results at baseline, at follow-up we only found a significant
correlation between PU (according to PUTS) and BAI (r= 0.496,
p= 0.036), but not with any other assessment for comorbidities.
Comorbidities
In relation to psychiatric comorbidities, our results indicated
that aripiprazole caused a significant impact on psychiatric
comorbidities. Specifically, the number of patients with the
diagnosis of “GTS only” increased from N = 6 at baseline to
N = 8 at follow-up, and the diagnosis of “GTS plus” decreased
from N = 12 to N = 10 patients. With respect to above defined
subgroups, the number of patients with “GTS+OCD” decreased
from N = 6 to N = 2 patients, with “GTS+OCD+ADHD” from
N = 3 to N = 2, but remained unchanged for the subgroup
“GTS+ADHD” (N = 1) (see Table 1 for an overview).
With respect to the specific comorbidities, we discuss below
all the clinical changes observed at follow-up in comparison to
baseline (Figure 1). Treatment with aripiprazole resulted in a
significant improvement of OCD. At baseline, the diagnosis of
OCDwasmade in 9 patients (50%), but only in 5 patients (27.8%)
after treatment (p= 0.046). None of the patients developed OCD
during treatment. However, no significant changes were observed
in the respective assessments for OCD at follow-up compared to
baseline [Y-BOCS (p= 0.445), M.I.N.I. OCD current (p= 0.317),
OCI-R (p= 0.585)].
For depression, although the total number of diagnosed
patients decreased from 6 (33.33%) at baseline to 4 patients
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TABLE 2 | Clinical characteristics at baseline and follow-up.
Assessment Patients not treated Patients treated with aripiprazole (N = 18)
with aripiprazole (N = 26)
Mean (SD) Mean (SD) Mean (SD) Difference between
Baseline Baseline Follow-up Baseline and Follow-up
Tics YGTSS -TTS 21.8 (±9.1) 22.7 (±7.9) 19.2 (+7.5) −3.5*
MT 12.8 (±4.5) 13.7 (±3.4) 11.8 (+3.4) −1.9*
VT 9.4 (±6.2) 9.0 (±5.8) 7.4 (±5.4) −1.6*
GS 42.5 (±17.8) 50.9 (±17.2) 35.9 (±17.4) −15.0**
MRVS 8.9 (±4.7) 10.4 (±5.5) 8.0 (±4.2) −2.4*
PU PUTS 21.8 (±5.9) 19.7 (±6.1) 19.8 (±5.5) +0.1
OCD Clinical diagnosis N = 6 N = 9 N = 5 −4*
M.I.N.I. OCD current N = 6 N = 9 N = 7 −2
Y-BOCS 3.7 (±6.9) 5.3 (±6.9) 4.2 (±5.5) −1.1
Obsessions 1.2 (±3.6) 1.7 (±3.5) 1.3 (±3.5) −0.4
Compulsions 2.5 (±4.4) 3.7 (±4.9) 3.0 (±4.9) −0.7
OCI-R 16.6 (±15.0) 15.5 (±11.6) 14.6 (±13.8) −0.9
Washing 0.9 (+1.9) 0.8 (±1.20) 1.6 (±2.85) +0.8
Obsessing 3.2 (±3.3) 2.7 (±2.6) 2.6 (±2.5) −0.1
Hoarding 3.2 (±2.7) 2.1 (±2.8) 2.1 (±2.9) −
Ordering 3.7 (±3.2) 4.3 (±3.3) 3.4 (±3.1) −0.9
Mental neutralization 1.4 (±2.1) 2.0 (±2.5) 2.2 (±2.9) +0.2
Checking 3.7 (±3.4) 3.6 (±3.3) 2.8 (±3.3) −0.8
Depression Clinical diagnosis N = 8 N = 6 N = 4 −2
M.I.N.I. MD current N = 5 N = 3 N = 1 −2
BDI-II 12.8 (±12.9) 13.7 (±10.8) 10.6 (±8.20) −3.1
MADRS 8.7 (±8.27) 7.2 (±5.6) 8.6 (±4.00) +1.4
Anxiety Clinical diagnosis N = 9 N = 6 N = 4 −2
M.I.N.I. panic current N = 3 N = 1 N = 1 −
agoraphobia N = 4 N = 3 N = 3 −
social phobia N = 1 N = 0 N = 0 −
GAD N = 2 N = 1 N = 1 −
BAI 13.8 (±13.8) 9.4 (±8.7) 8.6 (±7.0) −0.8
Autistic traits AQ 18.2 (±8.4) 19.3 (±7.7) 19.7 (±7.2) +0.4
ADHD Clinical diagnosis N = 12 N = 4 N = 3 −1
CAARS Inattention 50.4 (±13.2) 50.6 (±10.4) 47.9 (±7.3) −2.7
Hyperactivity-Restless 51.6 (±9.9) 51.9 (±11.3) 51.4 (±9.9) −0.5
Impulsivity 50.8 (±10.2) 52.5 (±11.9) 50.5 (±11.5) −2
Selfconcept 48.8 (±8.9) 47.6 (±8.9) 48.5 (±8.30) +0.9
Inattentive 53.1 (±15.6) 52.8 (±15.7) 54.7 (±13.9) +1.9
Hyperactive-Impulsive 51.4 (±13.3) 51.1 (±14.4) 51.5 (±9.4) +0.4
ADHD total 53.1 (±14.8) 52.3 (±14.9) 54.2 (±12.3) +1.9
ADHD index 53.1 (±11.2) 53.8 (±11.5) 53.8 (±9.6) −
WURS-k 35.3 (±15.5) 29.2 (±12.8) − −
DSM-IV Attention 4.3 (±2.9) 4.3 (±3.2) − −
Hyperactivity 3.5 (±3.1) 2.7 (±2.4) − −
(Continued)
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TABLE 2 | Continued
Assessment Patients not treated Patients treated with aripiprazole (N = 18)
with aripiprazole (N = 26)
Mean (SD) Mean (SD) Mean (SD) Difference between
Baseline Baseline Follow-up Baseline and Follow-up
QoL GTS-QoL 33.4 (±23.8) 26.7 (±16.1) 24.5 (±17.1) −2.2
GTS-QoL-VAS 61.5 (±27.3) 60.6 (±20.5) 67.1 (±19.4) +6.5
YGTSS, Yale Global Tic Severity Scale; TTS, Total Tic Score; MT, Motor Tic Score; VT, Vocal Tic Score; GS, Global Score; MRVS, Modified Rush Video-Based Tic Scale; PU, Premonitory
Urge; PUTS, Premonitory Urge for Tics Scale; OCD, Obsessive-Compulsive Disorder; M.I.N.I., International Neuropsychiatric Interview; Y-BOCS, Yale-Brown Obsessive Compulsive
Scale; OCI-R, Obsessive-Compulsive Inventory Revised; MD, Major Depression; BDI, Beck Depression Inventory; MADRS, Montgomery Asberg Depression; GAD, Generalized Anxiety
Disorder; BAI, Beck Anxiety Inventory, AQ, Autism-Spectrum-Quotient; ADHD, Attention-Deficit/Hyperactivity Disorder; CAARS, Conners Adult ADHD Rating Scale (for patients treated
with aripiprazole, CAARS scores are given for N = 15/17 due to missing data), WURS-k, Wender Utah Rating Scale; DSM, Diagnostic and Statistical Manual; QoL, Quality of Life (the
higher the sum, the lower the QoL); VAS, Visual Analogue Scale (the higher the sum, the higher the satisfaction). Clinical diagnosis, Diagnoses for comorbidities as defined above; N,
Number of cases. *p < 0.05, **p < 0.01.
TABLE 3 | Correlates of Premonitory Urges (as assessed by PUTS) and Quality of Life (as assessed by GTS-QoL and GTS-QoL-VAS) at baseline (N = 44).
Assessments PUTS GTS-QoL GTS-QoL-VAS
r p-value r p-value r p-value
TICS
YGTSS-TTS 0.281 0.065 0.461** <0.01 −0.379* 0.011
YGTSS-GS 0.294 0.052 0.600**a <0.01 −0.609** <0.01
MRVS 0.042 0.790 0.139a 0.216 −0.330* 0.031
OCD
M.I.N.I. OCD current 0.258 0.091 0.223 0.146 −0.316* 0.036
OCI-R 0.244 0.111 0.571** <0.01 −0.509**a <0.01
Y-BOCS 0.340* 0.024 0.277 0.069 −0.322* 0.033
DEPRESSION
M.I.N.I. MD current 0.207 0.177 0.573*** <0.001 −0.589*** <0.001
BDI-II 0.276 0.070 0.776** <0.01 −0.680** <0.01
MADRS 0.293 0.054 0.790** <0.01 −0.731**a <0.01
ANXIETY
M.I.N.I. panic 0.250 0.102 0.417** 0.005 −0.353* 0.019
M.I.N.I. agoraphobia 0.246 0.108 0.335* 0.026 −0.314* 0.038
M.I.N.I. social phobia 0.187 0.225 0.234 0.126 −0.253 0.098
M.I.N.I. GAD −0.321* 0.034 0.185 0.230 −0.018 0.909
BAI 0.184a 0.229 0.672** <0.01 −0.577** <0.01
ADHD
DSM-IV Attention 0.313* 0.038 0.360* 0.016 −0.217 0.157
DSM-IV Hyperactivity 0.110 0.478 0.073 0.636 0.082 0.595
CAARS ADHD total 0.411* 0.013 0.583** <0.01 −0.302 0.073
WURS-k 0.256 0.098 0.421** <0.01 −0.211 0.175
AUTISTIC TRAITS
AQ 0.000 0.999 0.260 0.088 −0.209 0.174
PUTS, Premonitory Urge for Tics Scale; GTS, Gilles de la Tourette Syndrome; QoL, Quality of Life (the higher the sum, the lower the QoL); VAS, Visual Analogue Scale (the higher the sum,
the higher the satisfaction); YGTSS, Yale Global Tic Severity Scale; TTS, Total Tic Score; GS, Global Score; MRVS, Modified Rush Video-Based Tic Scale; OCD, Obsessive-Compulsive
Disorder; M.I.N.I., International Neuropsychiatric Interview; OCI-R, Obsessive-Compulsive Inventory Revised; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; MD,Major Depression;
BDI, Beck Depression Inventory; MADRS, Montgomery Asberg Depression Scale; GAD, Generalized Anxiety Disorder; BAI, Beck Anxiety Inventory; ADHD, Attention-Deficit/Hyperactivity
Disorder; DSM, Diagnostic and Statistical Manual; CAARS, Conners Adult ADHD Rating Scale; WURS-k, Wender Utah Rating Scale; AQ, Autism-Spectrum-Quotient. Correlation
coefficient is given as r, Spearman correlation. N = Number of cases. *p<0.05, **p < 0.01, ***p < 0.001. a = significant at follow-up.
(22.2%) upon treatment, this decrease was not significant
(p = 0.317). Notably, none of the patients developed comorbid
depression while treated with aripiprazole. None of the different
assessments for depression used in this study demonstrated
a significant improvement [MADRS (p = 0.245), BDI-II
(p= 0.201), M.I.N.I. MD current (p= 0.157)].
Frontiers in Neuroscience | www.frontiersin.org 7 September 2016 | Volume 10 | Article 416
Gerasch et al. Aripiprazole Improves Tics and Comorbidities
FIGURE 1 | Patients with respective comorbidity at baseline compared to follow-up, N = 18 (for definition of psychiatric comorbidities (OCD, ADHD,
depression, anxiety, and autistic traits) refer to chapter 2.3).
In 6 patients (33.33%) the diagnosis of anxiety disorder was
made at baseline. After the treatment period, the diagnosis was
still made in 4 patients (22.2%) resulting in a non-significant
difference (p = 0.157). None of the patients developed an
anxiety disorder during treatment with aripiprazole. Although
BAI scores decreased in 12 patients, in none of the single tests
a significant difference was seen [BAI (p= 0.163), M.I.N.I. social
phobia/agoraphobia/panic current/GAD (p= 0.100)].
The diagnosis of comorbid ADHD was made in 4 patients
(22.2%) at baseline and in 3 patients (16.7%) at follow-up
(p = 0.271). However, we found no significant changes in
respective assessments for ADHD at follow-up compared to
baseline [CAARS ADHD total (p= 0.272)].
Accordingly, the mean comorbidity score decreased from
1.38 at baseline to 1.16 at follow-up. Specifically, at follow-up,
1 patient suffered from 1 comorbidity (compared to N = 5 at
baseline), 8 patients from 2 (baseline N = 3), and 1 patient from
4 (baseline N = 2).
With respect to autism, of the 2 patients (11.1%), who
exhibited pathologically autistic traits (according to AQ) at
baseline, only 1 patient was still above the AQ cut-off at follow-up
(p= 0.721). However, absolute AQ scores improved in 8 patients.
QoL and Satisfaction-with-Life
With respect to patient’s QoL and satisfaction-with-life,
treatment with aripiprazole resulted in a non-significant
improvement as assessed by both GTS-QoL (difference: −2.2,
p = 0.760) and GTS-QoL-VAS (difference: +6.5, p = 0.106).
Comparable to baseline correlations in the whole sample
(N = 44), we found significant positive correlations at follow-up
(N = 18) between GTS-QoL and tic severity [YGTSS-GS
(r = 0.581, p = 0.011) and MRVS (r = 0.616, p = 0.007)]. Once
more, we found a negative and significant correlation between
assessments for depression [MADRS (r = −0.663, p = 0.003)]
and OCD [OCI-R (r =−0.492, p= 0.038)] with GTS-QoL-VAS.
All other correlations with GTS-QoL and GTS-QoL-VAS were
not significant.
Further details on clinical characteristics at follow-up
(N = 18) are given in Table 2 and Figure 1. In none of the tests
differences between male and female participants were detected.
Adverse Effects and Continuation of Treatment
12 out of 18 patients (66.7%) reported AEs (for details
see Table 4). However, the AEs experienced by the patients
were not severe, as no medical intervention was necessary
for any patient. After the end of the study, 14 patients
(77.77%) decided to continue treatment with aripiprazole. Four
patients stopped medication, among them three due to AEs
[drowsiness, restlessness, sleep disturbance, restlessness of legs
(akathisia)] and one due to no tic improvement. We found no
differences between male and female participants with respect to
reported AEs.
Comparison of Clinical Characteristics of
Patients Depending on their Decision
for/against Treatment with Aripiprazole
Of 44 patients included in this study, 18 patients elected
to undergo treatment for their tics with aripiprazole [mean
Frontiers in Neuroscience | www.frontiersin.org 8 September 2016 | Volume 10 | Article 416
Gerasch et al. Aripiprazole Improves Tics and Comorbidities
TABLE 4 | Reported adverse effects while taking aripiprazole (N = 18,
multiple answers possible).
Adverse effects N (%)
Sleep disturbance 8 (44.4)
Restlessness 3 (16.7)
Restlessness of legs (akathisia) 1 (5.6)
Obstipation 2 (11.1)
Drowsiness 2 (11.1)
Hot flushes 1 (5.6)
Cardiac/chest pain 1 (5.6)
Weight gain 1 (5.6)
Feeling depressive 1 (5.6)
age= 38.5 (±13.7) years, range, 18–56 years, female= 4, male=
14] while 26 patients [mean age= 40 (±11.4) years, range, 18–58
years, female= 5, male= 21] elected for no treatment.
The reasons for the patients’ decision were: (1) not interested
in taking medication at all, (2) lack of disabling impairments
by their tics, and (3) worries about possible AEs related to
aripiprazole.
Since this choice was solely based on the patients’ own
decision and neither on tic severity (according to YGTSS/MRVS;
see Figure 2), nor the advice of the treating physician or the
investigators, we compared the clinical characteristics between
both groups at baseline in order to identify factors that may
influence their decision for undergoing medical treatment for
their tics. Most interestingly, neither tic severity (according
to YGTSS and MRVS), nor PU (according to PUTS), nor
QoL (as assessed by GTS-QoL and GTS-QoL-VAS) were
significantly different between both groups. With respect to
comorbidities (OCD, ADHD, depression, and anxiety), we
observed that the diagnosis of comorbid OCD at baseline tended
to be significantly more common in patients who decided for
treatment with aripiprazole (9/18, 50%) compared to those
who decided against the treatment (6/26, 23.1%, p = 0.067).
With respect to comorbid ADHD, the opposite was the case
as the diagnosis of ADHD was made less in patients who
decided for treatment with aripiprazole (4/18, 22.2%) compared
to those, who decided against (12/26, 46.2%, p = 0.109) (see also
Figure 3).
When comparing both groups with respect to above defined
subgroups, we found no significant differences. The diagnosis
of “GTS only” was made in 6/18 (33.3%) patients, who decided
for treatment with aripiprazole, compared to 9/26 (34.6%), who
decided against treatment (p= 0.931). Accordingly, the diagnosis
of “GTS plus” was made in 12/18 (66.7%) patients, who decided
for treatment with aripiprazole, compared to 17/26 (65.4%)
who decided against (p = 0.931) (subgroups: “GTS+OCD”:
N = 2, “GTS+ADHD”: N = 8, “GTS+OCD+ADHD”: N = 4,
others: N = 3) (see Table 1). Accordingly, the mean comorbidity
score was comparable: 1.38 (range 0–4, N = 18) in patients,
who decided for treatment and 1.34 (range 0–4, N = 26)
in those, who decided against. When comparing results of
distinct assessments for psychiatric comorbidities, no significant
differences could be detected between both groups. Neither
gender nor age had any influence on patients’ decision for or
against treatment.
Serum Levels of Aripiprazole
Serum levels of aripiprazole were measured in 14/18 patients
(missing blood samples in N = 4) ranging from 7.5 to 269µg/L
[mean = 125.3 (±79.8 (SD)] (therapeutic range: 150–250µg/l).
Serum levels correlated significantly with administered oral
dosages of aripiprazole (2.5–30mg/day) (r = 0.7, p = 0.003)
indicating successful adherence to treatment.
DISCUSSION
This study is novel in two ways. Firstly, it is the first open-
label clinical trial with a prospective investigation of the effect of
aripiprazole on tic severity as well as on psychiatric comorbidities
in adult patients with GTS. Secondly, our study design allowed
us to investigate the factors that influence a patient’s decision
in undergoing pharmacotherapy of their tics for the first time.
Our results indicated that (1) aripiprazole is effective and safe for
the treatment of tics as well as for comorbid OCD and possibly
other comorbidities such as ADHD, depression and anxiety; (2)
aripiprazole has no influence on PU; (3) patients with comorbid
OCD are more likely to elect for undergoing medical treatment
for the treatment of their tics when compared to those with
comorbid ADHD; and (4) neither tic severity, nor PU, nor QoL
influence the patients decision making process.
Efficacy of Aripiprazole on Tics and PU
Our findings are in line with preliminary data (Padala et al.,
2005; Davies et al., 2006; Yoo et al., 2007, 2013; Budman
et al., 2008; Lyon et al., 2009; Ghanizadeh, 2012; Wenzel et al.,
2012) demonstrating that aripiprazole results in a significant
improvement of tics in the majority of adult patients with GTS.
This could be demonstrated by using both the examiner rating
scale YGTSS-TTS and the video-based assessment MRVS.
In contrast, aripiprazole did not result in a significant
improvement of PU. To the best of our knowledge, this is the
first study, investigating the effect of aripiprazole on PU in adult
patients with GTS. Thus, from our results it is suggested that
effective treatment of tics is possible without improvement of
PU. In addition, neither at baseline (N = 44), nor at follow-
up (N = 18), significant correlations between PU (as measured
by PUTS) and tic severity (according to YGTSS-TTS and -GS
and MRVS, respectively) were found. These findings, therefore,
further support recent clinical studies suggesting that PU is
not as closely related to tic severity as previously assumed
(Ganos et al., 2012; Müller-Vahl et al., 2014). In line with these
findings, from an increasing number of brain imaging studies it is
suggested that different brain areas are involved in the occurrence
of PU (supplementary motor area, insula, and mid-cingulate
cortex) and tics (thalamus, central operculum, primary motor,
somatosensory, premotor, and parietal cortices) (Bohlhalter et al.,
2006; Jackson et al., 2011; Neuner et al., 2014).
Our results showed a positive correlation between PU
(according to PUTS) and anxiety (according to BAI) at baseline.
This finding is in line with recent data demonstrating on the one
Frontiers in Neuroscience | www.frontiersin.org 9 September 2016 | Volume 10 | Article 416
Gerasch et al. Aripiprazole Improves Tics and Comorbidities
FIGURE 2 | Mean tic severity (according to YGTSS-TTS) at baseline (in whole sample and in those decided for vs. against treatment) and follow-up.
FIGURE 3 | Prevalence of comorbidities at baseline in patients who decided for vs. those who decided against treatment with aripiprazole (for
definition of psychiatric comorbidities (OCD, ADHD, depression, anxiety, and autistic traits) refer to chapter 2.3).
hand stronger PU in GTS patients with comorbidities compared
to those without and on the other hand a positive correlation
between PU and OCD (Eddy and Cavanna, 2013; Sambrani et al.,
2016).
Diagnoses for Comorbidities
For a thorough clinical characterization of our sample, a
number of clinical assessment tools were utilized to diagnose
and quantify each of the commonly associated psychiatric
comorbidities. Specifically, 3 rating scales were used for each
of obsessive-compulsive symptoms inattention/hyperactivity and
depressive symptoms, while 2 rating scales were used for anxiety.
Nevertheless, it is well known that the use of different
assessments—although developed for the measurement of the
same symptoms—may reflect different sides of the same disorder
and therefore, may lead to inconsistent findings. In addition,
it is generally accepted that patients’ self-perception may differ
from professional evaluation (Beblo and Lautenbacher, 2015)
resulting in discrepant results when using self-ratings compared
to examiner rating scales (Olariu et al., 2015). For example,
the subtle differences of commonly used depression rating
scales were pointed out by Uher et al. (2008), who showed
that the Hamilton Rating Scale for Depression (HAMD-17),
MADRS and BDI-II, while all being valid and reliable scales,
reflect “internally consistent but mutually distinct estimates of
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depression severity.” While the MADRS is closer to the core of
depression—observable from the outside—the BDI represents a
“cognitive” dimension—which is more of an internal experience.
Uher et al. (2008), therefore, recommended to use these scales in a
complementary fashion. Comparably, we found contrary results
when using the BDI-II as a self-rating compared to the MADRS
as an expert rating: while treatment with aripiprazole resulted in a
decrease in mean BDI-II values, mean MADRS scores increased.
A closer investigation showed that this obvious inconsistency
was due to the high incidence of “sleep disturbances” (44.4%)
and “internal unrest” (16.7%), which were the most frequently
reported AEs during treatment with aripiprazole. While having
little impact on the BDI-II score, the presence of these symptoms
had a considerably high impact on the MADRS scores leading
erroneously to high scores for depression.
Similar findings were reported for OCD, where the Y-BOCS
was shown to represent a better measure for symptom severity
and the OCI-R was shown to be primarily a measure of symptom
presence (Sulkowski et al., 2008) and for ADHD ratings (Rösler
et al., 2006). Taylor et al. (2011) report CAARS and WURS-
k as the most robust ADHD scales with content validity,
compared with 12 other ADHD scales. The same was true for
anxiety ratings, where the discriminant validity of generally used
anxiety screening was reported (Phan et al., 2016). In addition,
limitations of the M.I.N.I. in assigning anxiety disorders are well
known, since it includes only four, but not all categories for
anxiety disorders as defined in the ICD-10.
To overcome these methodological difficulties and to help
balance the advantages and disadvantages of self-report and
clinician-ratings, we therefore decided to make the diagnoses
of both OCD, ADHD, depression and anxiety, not only based
on any single (arbitrarily selected) rating scale, but on the
combination of several scales. While this procedure is well
accepted for the diagnosis of ADHD (Rösler et al., 2006), it is
less established in the context of other diagnoses such as OCD,
depression, and anxiety. We are aware that in most other clinical
trials diagnoses of comorbidities and changes during treatment
are only based on one single assessment. However, we believe
that this concept may result in more robust diagnoses and may
avoid false positive and negative results. In addition, we want
to stimulate a discussion about the diagnostic procedure of
comorbidities in patients with GTS. It is well known that both
depressive (Trillini andMüller-Vahl, 2015b) and OCD symptoms
(Worbe et al., 2010) in this group of patients may differ from
those in patients without GTS and therefore well-established
instruments for these diagnoses (without GTS) might be less
suitable in patients with GTS.
Efficacy of Aripiprazole on Comorbidities
According to diagnoses defined in these terms, treatment with
aripiprazole resulted in a significant improvement of OCD
(although respective assessments for OCD demonstrated no
significant changes at follow-up compared to baseline). Due
to the small number of patients, results in other psychiatric
comorbidities did not reach statistical significance. However,
according to this concept, treatment with aripiprazole, in
addition, resulted in remission of comorbid depression in 4
of 6 patients, of comorbid anxiety in 4 of 6 patients, and of
comorbid ADHD in 1 of 4 patients. Accordingly, the mean
comorbidity score decreased from 1.38 at baseline to 1.16 at
follow-up. Furthermore, pathologically autistic traits changed in
1 of 2 patients and absolute scores (according to AQ) improved
in 8 patients.
Our findings corroborate available case reports in patients
with GTS reporting about beneficial effects of aripiprazole in
the treatment of depression (Murphy et al., 2009; Wenzel et al.,
2012), OCD (Murphy et al., 2005, 2009; Winter et al., 2008),
anxiety, self-injurious behavior (Wenzel et al., 2012), inattention
(Murphy et al., 2009), and ADHD (Masi et al., 2012), but in
contrast to preliminary results by Frölich et al. (2010) who found
no improvement of ADHD and OCD in children with GTS.
However, in none of these studies the effect of aripiprazole has
been investigated specifically for the treatment of psychiatric
comorbidities, comorbidities were not assessed by using a variety
of self- and examiner-ratings, and, at least in part, data were
collected retrospectively from patient records.
Furthermore, our findings in patients withGTS are completely
in line with data in patients with pure OCD, where aripiprazole
has been found to be effective not only in the treatment of
uncomplicated OCD (Sayyah et al., 2012), but even in patients
resistant to treatment with selective serotonin reuptake inhibitors
(SSRI) (Delle Chiaie et al., 2011; Masi et al., 2013; Dold et al.,
2015; Shoja Shafti and Kaviani, 2015). Aripiprazole has also been
found helpful in the treatment of depression (Wen et al., 2014)
and anxiety disorders (Pae et al., 2008; Katzman, 2011). It is even
one of the most often prescribed medication in patients with
anxiety and mood disorders (Carton et al., 2015). Although often
prescribed in ADHD (Carton et al., 2015) its efficacy has not been
shown (Ghanizadeh, 2013).
The effective influence of aripiprazole on a number of
psychiatric conditions has been suggested to be a result of
its unique pharmacological profile. Specifically, aripiprazole
is a functionally selective drug that exhibits an adaptive
pharmacological profile that is dependent on the local levels
of the endogenous ligands. Aripiprazole is a partial dopamine
D2 agonist, a partial serotonin 5-HT1A agonist, and a
5-HT2A antagonist. Apart from its recognized influence
on the dopaminergic and serotonergic systems, aripiprazole
has also been shown to modulate the glutamatergic and
GABAergic neurotransmitter systems (De Bartolomeis et al.,
2015). Therefore, it can be speculated that beneficial effects of
aripiprazole on OCD, depression and anxiety in patients with
GTS may be the result of its ability to selectively and adaptively
stabilize multiple neurotransmitter systems.
Influence of Aripiprazole on Quality of Life
Comparable to previous reports by Müller-Vahl et al. (2010) and
Jalenques et al. (2012), we found that in adult patients with GTS
both QoL and satisfaction-with-life (as assessed by GTS-QoL
and GTS-QoL-VAS) are mainly impaired by depression. This
was true at baseline and also during treatment with aripiprazole.
Although aripiprazole resulted in a significant improvement
of tics, we only found a trend toward an improvement in
patients’ QoL. This is in line with the finding that depression
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influences patients’ QoL more than the tics. Interestingly, we
found a significant correlation between PU and QoL at baseline.
Assuming that PU is a kind of an OCB as suggested recently
(Sambrani et al., 2016) and against the background that it is
well-known that OCD significantly impairs QoL in adult patients
with GTS (Müller-Vahl et al., 2010), this correlation can possibly
be explained by the negative influence of OCD on patients’
QoL. The complex interplay between tics, comorbidities, and
QoL is also expressed in changes in the YGTSS-GS: this “global
score” of the YGTSS is a measurement for both tic severity and
overall impairment. Completely in line with all above mentioned
results, after treatment with aripiprazole we found amuch greater
reduction of the YGTSS-GS (p= 0.002) compared to the tic score
of the YGTSS (YGTSS-TTS, p= 0.027).
Adverse Effects of Aripiprazole
Although AEs were reported by a substantial number of patients
(66.7%), most AEs were mild and/or tolerable corroborating
recent data that in most adult patients with GTS aripiprazole is
well tolerated (Lyon et al., 2009; Wenzel et al., 2012; Diomšina
et al., 2015). No serious AEs occurred. Three of eighteen patients
(16.7%) decided to stop treatment with aripiprazole due to
AEs such as drowsiness, restlessness, sleep disturbance, and
restlessness of legs (akathisia). Comparable to our data, Wenzel
et al. (2012) also reported about the occurrence of AEs in nearly
2/3 (59%) of their patients. However, in contrast to our results,
they found drowsiness (20%) to be the most common side effect,
while sleep disturbances were quite rare (9%). In this study,
sleep disturbances (44.4%) followed by restlessness (16.7%) were
the most often reported AEs, while drowsiness occurred in only
11.1% of our patients. This difference might be explained by
different study designs and different treatment durations (4–6
weeks in our study vs. 1–60 months in Wenzel et al., 2012).
Hence, it can be assumed that in the context of a longer-
term treatment, patients may tolerate drowsiness rather than
restlessness and sleep disturbances. Nonetheless, our data further
support the clinical practice to start treatment with aripiprazole
once daily in the morning, and to postpone intake to the evening,
if significant drowsiness occurs.
Decision Factors for Treatment with
Aripiprazole
Our study design provided us with the possibility of investigating
the factors that influence patient’s decision in electing for—
or against—treatment. This choice was solely based on each
patient’s own preference. We found no differences between both
groups with respect to age, gender, and comorbidity score.
Most interestingly, neither tic severity (according to YGTSS and
MRVS), nor PU (according to PUTS) nor QoL (as assessed
by GTS-QoL and GTS-QoL-VAS) was significantly different
between both groups. However, we found a trend with respect
to comorbid OCD and ADHD. While OCD was more common
in those patients who decided for treatment with aripiprazole,
ADHD was more common in those who decided against. Thus,
although not reaching the significance threshold, our data seems
to indicate that there are aspects influencing patients’ decisions
for or against medical treatment for tics beyond tic severity. Since
comorbid OCD has a strong negative impact on patients’ QoL,
it can be speculated that this might be a driving force that also
influences patients’ treatment decision in favor of treatment for
tics. However, it can also be possible that patients with comorbid
OCD differ in their assessment of impairment caused by their tics
as compared to patients without OCD, possibly due to a larger
extent of ruminating and worrying caused by their compulsions.
Finally, it can be hypothesized that patients with comorbid
ADHD are less impaired by their tics and therefore tend to decide
against treatment. This is particularly noteworthy, since it has
been demonstrated that patients with comorbid ADHD are less
able to suppress their tics (Sambrani et al., 2016) and effective
tic suppression has a positive impact on patients’ QoL (Matsuda
et al., 2016).
Characteristics of the Sample and Serum
Levels of Aripiprazole
With respect to tic severity, comorbidities, and distribution of
gender, in this open-label study a representative clinic sample
of adult patients with GTS was included. Although, all patients
participating in this study, in addition, participated in an
MRI study—and therefore patients also had to fulfill inclusion
criteria for that study—our group of patients was characterized
by moderate tics (mean tic severity = 22.2 according to
YGTSS-TTS, N = 44). Usually, a threshold of YGTSS-TTS
>14 indicates clinically significant tics that justify treatment
(Leckman et al., 1989; Wilhelm et al., 2012). In contrast to
most other studies investigating the efficacy of aripiprazole in
patients with GTS, we included only adults > age of 18 years.
It is noteworthy that all patients who received treatment with
aripiprazole were otherwise free of any other psychoactive drug
for at least 4 weeks before entering the study. Thus, interactions
with other psychoactive substances or augmentation effects are
not of concern. Measurements of serum levels of aripiprazole
demonstrated patient adherence. For the first time, we were able
to show positive correlation between oral dosage and serum levels
of aripiprazole in this group of patients.
Limitations
There are the following limitations of the study: (1) no patient
control group with either placebo or another active drug was
included, (2) we included different groups of patients (mildly
vs. severely affected patients, pretreated vs. drug-naive patients,
and patients with vs. without comorbidities), (3) the number of
patients undergoing treatment was relatively low, (4) given that
treatment duration was relatively short (only 4–6 weeks) and that
(5) aripiprazole’s long half-life of approximately 72 h, we cannot
rule out that aripiprazole levels were still increasing at the follow-
up assessment. (6) Most of the patients were recruited from the
Clinic of Psychiatry, Socialpsychiatry and Psychotherapy at the
MHH and, therefore, we cannot exclude a bias toward more
severely and complex affected patients as well as a selection bias,
(7) only those patients were assessed who agreed to participate
in the study and only those were reassessed who decided in
favor of treatment with aripiprazole, which decreases the external
validity of our trial, (8) we cannot exclude that patients decided
for participation in the study at baseline and/or follow-up due
Frontiers in Neuroscience | www.frontiersin.org 12 September 2016 | Volume 10 | Article 416
Gerasch et al. Aripiprazole Improves Tics and Comorbidities
to monetary compensation, and (9) declining the participation
at follow-up due to reluctance of travel and/or discomfort in
the MRI, (10) from our data, it cannot be excluded that other
factors than comorbid OCD and ADHD may influence patients’
decisions making process for or against medical treatment of
their tics.
The strengths of this study are: (1) the inclusion of a relatively
large number of patients, (2) at baseline, all patients were
drug-free, (3) a combination of several validated assessment
instruments insured the integration of the benefits of both
clinician rating and self-ratings for the diagnoses of psychiatric
comorbidities including OCD, ADHD, depression and anxiety,
(4) monotherapy with aripiprazole, enabled the exclusion of
influence of interactions with other drugs, (5) direct comparison
of groups of patients, electing for and against treatment
with aripiprazole was conducted, (6) confirmation of patients’
treatment adherence by determination of serum levels of
aripiprazole, and (7) the self-selection of patients in our study has
a high external validity, since these would be the patients opting
for aripiprazole in the clinic.
CONCLUSION
To the best of our knowledge, this is the first prospective open-
label clinical trial with a larger sample examining untreated adult
patients with GTS before and after a treatment period of 4–
6 weeks with aripiprazole monotherapy. The major findings of
the study are: (1) aripiprazole results in significant reduction
of tics in adult patients with GTS, but it does not affect PU;
(2) aripiprazole results in significant reduction of OCD and
possibly other comorbidities including depression, anxiety, and
ADHD; (3) patients with GTS with comorbid OCD tend to
decide for treatment of tics with aripiprazole, whereas patients
with comorbid ADHD tend to decide against this kind of
medication; (4) neither tic severity, nor PU or QoL influence
patients’ decisionmaking process for or against treatment of their
tics with aripiprazole, (5) aripiprazole appears safe and AEs are
commonly tolerable; and (6) patients’ QoL is mostly impaired by
comorbid depression. For further clinical trials it is suggested to
use a large variety of different rating scales in order to capture and
assess psychiatric comorbidities in patients with GTS.
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